The American health care giant Johnson & Johnson made a formal bid on Wednesday for Crucell, offering to pay 1.75 billion euros ($2.3 billion) for the rest of the Dutch biotechnology company.
Johnson & Johnson, which already owns 17.9 percent of Crucell, is offering 24.75 euros a share, 58 percent above the closing price on Sept. 16, the day before Johnson & Johnson first announced its intention to buy Crucell.
The Crucell board, which fully supports the deal, will bring the offer to a shareholder vote on Feb. 8. The minimum acceptance level will be 80 percent of the shares, assuming certain conditions are met.
WATCH: OBAMA ON THE DEFENSIVE OVER THE TAX PLAN